Press Releases Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
455.3 ^USD	+2.77%		-0.35%	+11.91%

May. 31	BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $500 From $480	MT
May. 31	Vertex Pharmaceuticals Insider Sold Shares Worth $1,478,068, According to a Recent SEC Filing	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Vertex to Participate in Upcoming June Investor Conferences	May. 22	BU
Jennifer Schneider Elected to Vertex Board of Directors	May. 15	BU
Vertex: Q1 Earnings Snapshot	May. 06	AQ
Vertex Reports First Quarter 2024 Financial Results	May. 06	BU
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older	Apr. 26	BU
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES	Apr. 23	PR
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES	Apr. 23	AQ
Vertex Announces Advancements of Suzetrigine in Acute and Neuropathic Pain	Apr. 19	AQ
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain	Apr. 18	BU
Vertex Pharma scientist talks about the long road to developing non-addictive painkillers	Apr. 15	AQ
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences	Apr. 10	BU
Vertex to Announce First Quarter 2024 Financial Results on May 6	Apr. 09	BU
Vertex Advances Inaxaplin into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease	Apr. 02	AQ
Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia	Apr. 01	AQ
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease	Apr. 01	BU
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey	Mar. 28	AQ
InvestorBrandMedia: FDA Approves Vertex Pharmaceuticals (NASDAQ:VRTX) VX-407 for Phase I Study in Groundbreaking Move Against Polycystic Kidney Disease"	Mar. 25	AQ
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	Mar. 22	AQ
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Mar. 21	BU
Vertex Pharmaceuticals Incorporated : ID&E Fact Sheet	Mar. 04	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Vertex Pharmaceuticals Incorporated : Vertex and Crispr to market $2.2 million treatment for sickle cell disease

December 11, 2023 at 05:47 am EST